Press Releases

February 3, 2023 Lupin Launches Aptivate Champion Run for Kids Promoting Well-being and Good Eating Habits

January 31, 2023 Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

January 24, 2023 Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care

January 18, 2023 Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

January 16, 2023 Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

January 10, 2023 Lupin Receives Approval from U.S. FDA for Prasugrel Tablets, USP

January 9, 2023 Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders

January 6, 2023 Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

January 5, 2023 Lupin Launches novel fixed-dose triple drug combination DIFIZMA® DPI to Treat Inadequately Controlled Asthma